The novel IFNα-2b AOP2014 administered once every two weeks (or once a month) has low toxicity and induces high and sustained response rates in PV patients.
AOP2014 induces significant partial and complete molecular response rates, as reflected by reduction of JAK2 allelic burden.
PV Reporter interviewed Dr Heinz Gisslinger at ASH 2014
Dr Heinz Gisslinger from Vienna, Austria is a pioneer in treating MPN patients with Interferon (IFN). PV Reporter sits down with Dr Gisslinger at ASH 2014.